Fig. 1

Antibodies against integrins α3, αM, and αMβ2 de-differentiate human myofibroblasts from monocyte precursors. Freshly isolated human monocytes (A-D) were differentiated into myofibroblasts and subsequently treated with (A) α-αMβ2, α-αM, α-α3, or α-α2β1 antibodies or (B) leukadherin at the indicated concentrations over 1 week, and the number of remaining myofibroblasts was assessed by morphology. Monocyte-derived myofibroblasts were treated with antibodies at 500 ng/ml and leukadherin at 2 ng/ml and analyzed via flow cytometry for (C) αSMA⁺ collagen I⁺ double positive cells and (D) talin2⁺. n ranges from 3 to 15. * = statistical significance of P < 0.05, < 0.01, or < 0.001, significance vs isotype control antibody, (A and B) 2-way ANOVA (with Fisher’s LSD post test), (C and D) Student’s t-test. Myofibroblast images can be found in supplemental Fig. 4, and examples of gating strategy can be found in supplemental Fig. 5.